1 insider bought €2.6M of shares over the last 90 days, the latest filed 15 Sept 2026.
This page follows insider dealings at Carlsmed, Inc. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 16 filings signed by 13 insiders.
Every open-market trade in the period is a purchase: 1 purchase worth €2.6M, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Presidio Management Group XII, L.L.C. filed the largest purchase, €2.6M, on 15 September 2026. Those buying include 1 major shareholder.
The last purchase on record was published on 15 September 2026, which is 33 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 16 filings, this issuer sits below that mark. The full history, which starts in 2025, counts 1 purchase against no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Analysts rate Carlsmed, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$19.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 25 declarations
Carlsmed, Inc. is a company listed on the XNAS market. It specializes in developing innovative solutions in the healthcare sector.
Purchases our model currently ranks for the recommendations list.
All recommendations